Logo

Foundation Medicine: Cindy Perettie

Jan 19, 2021

Foundation Medicine, a Roche subsidiary, announced Cindy Perettie would be transitioning to Roche Diagnostics to lead the molecular lab solutions business, effective April 6. Perettie has been the CEO of Foundation Medicine since 2019 and previously served as senior VP with product strategy responsibility for the global oncology portfolio at Roche and Genentech. She also led global portfolio management for IVAX Pharmaceuticals and was the president of global development innovations at the Sarah Cannon Research Insitute in Nashville. In addition, she was previously the director of global program management at Élan Corporation in the United Kingdom. 

Brian Alexander, Foundation's chief medical officer and senior VP, will be the interim CEO for the company. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.